New test detects ovarian and 7 other cancers using simple blood sample.

Brentuximab vedotin (Adcetris) has now been approved by the European Commission for the treatment of patients with CD30-positive cutaneous T-cell lymphoma (CTCL) who have had at least 1 prior systemic therapy.

Lynparza (olaparib) is the first PARP inhibitor approved to treat breast cancer, and the first medicine ever for metastatic breast cancer who have a “BRCA” gene mutation.

Ocrevus (ocrelizumab), the first ever FDA approved medicine for primary progressive MS has now also been approved by the EMA.

A new study found that cabozantinib (Cabometyx) was more effective than everolimus in advanced renal cell carcinoma and bone metastases.

A groundbreaking year helping patients access the latest approved medicines.

Pembrolizumab showed positive results in heavily pretreated, PD-L1–positive advanced esophageal carcinoma.

Specific strains of intestinal bacteria can improve the response rate to immunotherapy for patients being treated for advanced melanoma.

Eight important updates in lung cancer.

Darzalex (daratumumab) combination under review as first-line option.

Immunotherapy nivolumab has been linked to HIV reservoir decrease in a lung cancer patient. 

In a pilot study immunotherapy proved active in some patients with metastatic, trastuzumab (Herceptin)-resistant HER2-positive breast cancer.

Is there substance to the claims that it's a groundbreaking treatment?

Researchers are suggesting that metastatic tumours in the lung can be successfully eradicated using cryotherapy – literally turning the masses into ice balls that are then resorbed by the body.

The FDA has approved the first biosimilar for the treatment of certain breast and stomach cancers.

Mavenclad (cladribine) has become the multiple sclerosis therapy of choice for 1 in 5 neurologists in Germany and the UK. Meanwhile, many European neurologists wait for Ocrevus (ocrelizumab).

A phase 3 study on lung cancer showed that Imfinzi (durvalumab) as a consolidation therapy reduced the risk of the disease progressing by 48 percent.

FDA approves Juluca (dolutegravir and rilpivirine) for the maintenance treatment of certain patients with HIV-1 infection.

We talk to Sera, our Medicines Sourcing Manager about why drug delays happen...

Why can it take us three to four weeks to deliver a medicine, and what can customers do to speed things up?

Why every little package is a big deal

Introducing a breakthrough known as 'CT1812'

How effective is alectinib (Alecensa)? The latest news and updates

 We live in an age where you can hop online to order a new brand of lipstick if it hasn’t been released yet in your country. 

Our review of the SOCAP social impact event in San Francisco.

An insight into the team, and how we constantly review our progress at TheSocialMedwork

Suggestions from cancer survivors and their children

Online counsellor Nicole Hind shares how to help our brains and bodies deal with a diagnosis.

An easy-to-understand infographic displaying the results from the clinical trial

A chat with our very first angel investor about patients, doctors and injecting innovation into the healthcare sector